Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
Chin Med J (Engl)
; 136(10): 1207-1215, 2023 May 20.
Article
in En
| MEDLINE
| ID: mdl-37010251
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Goserelin
Type of study:
Clinical_trials
Limits:
Humans
/
Male
Language:
En
Journal:
Chin Med J (Engl)
Year:
2023
Document type:
Article
Affiliation country:
China
Country of publication:
China